CN106061981A - 具有二硫化物基团的多核苷酸构建体 - Google Patents
具有二硫化物基团的多核苷酸构建体 Download PDFInfo
- Publication number
- CN106061981A CN106061981A CN201480072173.2A CN201480072173A CN106061981A CN 106061981 A CN106061981 A CN 106061981A CN 201480072173 A CN201480072173 A CN 201480072173A CN 106061981 A CN106061981 A CN 106061981A
- Authority
- CN
- China
- Prior art keywords
- group
- optionally substituted
- aryl
- alkyl
- polynucleotide construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCCc1c(C*C)cccc1SSI Chemical compound CCCc1c(C*C)cccc1SSI 0.000 description 15
- JBICRTSQQVVHFT-LZWSPWQCSA-N C/C=C(\N=C=C)/SSCc1ccccc1CCO Chemical compound C/C=C(\N=C=C)/SSCc1ccccc1CCO JBICRTSQQVVHFT-LZWSPWQCSA-N 0.000 description 1
- FERLUFUZVWIVCZ-UHFFFAOYSA-N C1C=CC=NC1SSC1N=CC=CC1 Chemical compound C1C=CC=NC1SSC1N=CC=CC1 FERLUFUZVWIVCZ-UHFFFAOYSA-N 0.000 description 1
- LMFZZNGVOSXLJH-UHFFFAOYSA-N CC(C)(C)SS(C)CC1=C(COPN)CCC=C1 Chemical compound CC(C)(C)SS(C)CC1=C(COPN)CCC=C1 LMFZZNGVOSXLJH-UHFFFAOYSA-N 0.000 description 1
- SFDDBEKOGNPOLN-UHFFFAOYSA-N CC(C)(C)SSc1ccc(CO)cc1 Chemical compound CC(C)(C)SSc1ccc(CO)cc1 SFDDBEKOGNPOLN-UHFFFAOYSA-N 0.000 description 1
- KKTLBFAYKKEDNY-UHFFFAOYSA-N CC(C)(CN1CCCCC1)SSCCCCO Chemical compound CC(C)(CN1CCCCC1)SSCCCCO KKTLBFAYKKEDNY-UHFFFAOYSA-N 0.000 description 1
- XWLGMYNRPUNHSW-PFJIUMNCSA-O CC(C)CCCNC(CC/C=C\C(\C=[NH+]/N/C(/C)=C/C/C=C(\C(C)O)/C=N)=C/C)=O Chemical compound CC(C)CCCNC(CC/C=C\C(\C=[NH+]/N/C(/C)=C/C/C=C(\C(C)O)/C=N)=C/C)=O XWLGMYNRPUNHSW-PFJIUMNCSA-O 0.000 description 1
- SIEUNXOROYDZBQ-UHFFFAOYSA-N CC(CCCO)SSc1ccccn1 Chemical compound CC(CCCO)SSc1ccccn1 SIEUNXOROYDZBQ-UHFFFAOYSA-N 0.000 description 1
- ALVSEZZLFXRSRZ-UHFFFAOYSA-N CCC1(CC)COC(c(cc2)ccc2C(O)=O)OC1 Chemical compound CCC1(CC)COC(c(cc2)ccc2C(O)=O)OC1 ALVSEZZLFXRSRZ-UHFFFAOYSA-N 0.000 description 1
- OCRIRWLDWGXNFM-ICJLCFDTSA-N CC[C@H](C(C1F)OC)OC1N(C=CC(N1)=O)C1=O Chemical compound CC[C@H](C(C1F)OC)OC1N(C=CC(N1)=O)C1=O OCRIRWLDWGXNFM-ICJLCFDTSA-N 0.000 description 1
- BCCFCNDGMDLWMI-CYBMUJFWSA-N C[C@H](c1c(CCO)ccc(C)c1)Sc1ccccn1 Chemical compound C[C@H](c1c(CCO)ccc(C)c1)Sc1ccccn1 BCCFCNDGMDLWMI-CYBMUJFWSA-N 0.000 description 1
- QDKDCMQRAKMBPF-UHFFFAOYSA-N Cc1cnn[n]1C Chemical compound Cc1cnn[n]1C QDKDCMQRAKMBPF-UHFFFAOYSA-N 0.000 description 1
- GJWDFNPJVZQRMF-UHFFFAOYSA-N NCC(c(cc1)ccc1C(O)=O)=O Chemical compound NCC(c(cc1)ccc1C(O)=O)=O GJWDFNPJVZQRMF-UHFFFAOYSA-N 0.000 description 1
- GXNLKOPIZROXAP-SOFGYWHQSA-N O/C=C1/C(CBr)=CC=CC1 Chemical compound O/C=C1/C(CBr)=CC=CC1 GXNLKOPIZROXAP-SOFGYWHQSA-N 0.000 description 1
- PGFICWDBHLNKJY-UHFFFAOYSA-N OCCC1C=CCCC1CS Chemical compound OCCC1C=CCCC1CS PGFICWDBHLNKJY-UHFFFAOYSA-N 0.000 description 1
- OWHDVSYZMZCEML-UHFFFAOYSA-N OCCCc(cccc1)c1SSc1ncccc1 Chemical compound OCCCc(cccc1)c1SSc1ncccc1 OWHDVSYZMZCEML-UHFFFAOYSA-N 0.000 description 1
- OXZIGHSICAZCRV-UHFFFAOYSA-N OCc(cc1)ccc1SSc1ccccn1 Chemical compound OCc(cc1)ccc1SSc1ccccn1 OXZIGHSICAZCRV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/311—Phosphotriesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900685P | 2013-11-06 | 2013-11-06 | |
| US61/900685 | 2013-11-06 | ||
| US201461975686P | 2014-04-04 | 2014-04-04 | |
| US61/975686 | 2014-04-04 | ||
| US201462008906P | 2014-06-06 | 2014-06-06 | |
| US62/008906 | 2014-06-06 | ||
| PCT/US2014/064401 WO2015069932A1 (en) | 2013-11-06 | 2014-11-06 | Polynucleotide constructs having disulfide groups |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106061981A true CN106061981A (zh) | 2016-10-26 |
Family
ID=53042090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480072173.2A Pending CN106061981A (zh) | 2013-11-06 | 2014-11-06 | 具有二硫化物基团的多核苷酸构建体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160257961A1 (enExample) |
| EP (1) | EP3066105A4 (enExample) |
| JP (1) | JP2016537027A (enExample) |
| CN (1) | CN106061981A (enExample) |
| AU (1) | AU2014346658A1 (enExample) |
| CA (1) | CA2929651A1 (enExample) |
| WO (1) | WO2015069932A1 (enExample) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105037739A (zh) * | 2015-07-28 | 2015-11-11 | 四川大学 | 具有精氨酸穿膜作用的还原敏感型聚合物及其制备方法与应用 |
| CN109384715A (zh) * | 2018-11-19 | 2019-02-26 | 复旦大学附属肿瘤医院 | 前列腺特异性膜抗原的小分子抑制剂的制备方法 |
| CN109982998A (zh) * | 2016-11-23 | 2019-07-05 | 癌靶技术有限责任公司 | 白蛋白结合psma抑制剂 |
| CN110023321A (zh) * | 2016-08-17 | 2019-07-16 | 索尔斯蒂斯生物有限公司 | 多核苷酸构建体 |
| CN112402620A (zh) * | 2020-12-07 | 2021-02-26 | 南开大学 | 肿瘤微环境还原响应性的纳米药物及其制备方法 |
| WO2022161452A1 (zh) * | 2021-01-28 | 2022-08-04 | 南京桦冠生物技术有限公司 | 缀合物及其用途 |
| CN115244064A (zh) * | 2018-12-28 | 2022-10-25 | 圣诺制药公司 | 治疗性分子的靶向递送 |
| CN115925586A (zh) * | 2022-11-01 | 2023-04-07 | 青岛蓝谷多肽生物医药科技有限公司 | 一种靶向psma的母体及其衍生物的制备方法 |
| CN116715624A (zh) * | 2023-06-14 | 2023-09-08 | 信阳师范学院 | 一种n-烷基化吡啶硫酮类化合物的合成方法 |
| WO2024093947A1 (zh) * | 2022-10-31 | 2024-05-10 | 大睿生物医药科技(上海)有限公司 | 向细胞内递送siRNA的前药 |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015088990A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
| CN107109405A (zh) * | 2014-06-06 | 2017-08-29 | 索尔斯蒂斯生物有限公司 | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| CN105175546A (zh) * | 2015-05-27 | 2015-12-23 | 连祺周 | 人血管内皮生长因子与表皮生长因子样结构域7的融合蛋白 |
| WO2016208773A1 (ja) * | 2015-06-26 | 2016-12-29 | 協和発酵キリン株式会社 | オリゴヌクレオチド誘導体 |
| US10336785B2 (en) * | 2015-11-06 | 2019-07-02 | Qiagen Sciences, Llc | Methods for synthesizing nucleotide analogues with disulfide linkers |
| EP3386517A4 (en) * | 2015-12-08 | 2019-08-07 | Solstice Biologics, Ltd. | POLYNUCLEOTIDE CONSTRUCTS COMPRISING AN AUXILIARY FRACTION RELATED NON-BIOREVERSIBLE TO AN INTERNETOSIDIC PHOSPHATE OR PHOSPHOROTHIOATE |
| EP3429618B1 (en) | 2016-03-16 | 2024-02-21 | Amal Therapeutics SA | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
| AU2017287536B9 (en) * | 2016-06-30 | 2021-03-25 | Kyowa Kirin Co., Ltd. | Nucleic acid complex |
| MX392700B (es) | 2016-08-10 | 2025-03-11 | Cancer Targeted Tech Llc | Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados. |
| MX2019002075A (es) * | 2016-08-23 | 2019-07-01 | Dicerna Pharmaceuticals Inc | Composiciones que comprenden oligonucleotidos modificados reversiblemente, y sus usos. |
| KR20190057345A (ko) | 2016-09-21 | 2019-05-28 | 아말 테라퓨틱스 에스에이 | 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체 |
| BR112019021520A2 (pt) * | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
| AU2019222767A1 (en) | 2018-02-14 | 2020-08-27 | Deep Genomics Incorporated | Oligonucleotide therapy for Wilson disease |
| AU2019360216A1 (en) * | 2018-10-17 | 2021-05-13 | Tallac Therapeutics, Inc. | Immunomodulating polynucleotide conjugates and methods of use |
| CA3164050A1 (en) | 2019-12-09 | 2021-06-17 | Empirico Inc. | Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases |
| IL295759A (en) | 2020-02-28 | 2022-10-01 | Tallac Therapeutics Inc | Transglutaminase mediated coupling |
| US20240343746A1 (en) * | 2020-12-31 | 2024-10-17 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
| CN112679583B (zh) * | 2021-01-07 | 2022-02-22 | 杭州医学院 | 一种靶向癌蛋白boris的特异性多肽及其应用和基因 |
| CN112898206A (zh) * | 2021-02-05 | 2021-06-04 | 河北凡博医药科技有限公司 | 一种5,6-二甲基苯并咪唑的制备方法 |
| CN113024854B (zh) * | 2021-03-24 | 2022-06-03 | 西南石油大学 | 一种结构可控且规整的凝胶材料的制备方法 |
| IL315546A (en) | 2022-03-16 | 2024-11-01 | Empirico Inc | GALNAC compositions to improve siRNA bioavailability |
| TW202430637A (zh) | 2022-11-16 | 2024-08-01 | 美商戴瑟納製藥股份有限公司 | Stat3靶向性寡核苷酸及其用途 |
| WO2025160446A1 (en) * | 2024-01-25 | 2025-07-31 | Ai Proteins, Inc. | Methods and systems for characterizing structural features of a protein |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610841B1 (en) * | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
| CN102459302A (zh) * | 2009-06-01 | 2012-05-16 | 加利福尼亚大学董事会 | 核酸递送组合物及其使用方法 |
| WO2013126034A1 (en) * | 2012-02-22 | 2013-08-29 | Chemgenes Corporation | Synthesis of high purity dmt-c3-disulfide phosphoramidite |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7759291A (en) * | 1990-03-29 | 1991-10-21 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
| US20070142267A1 (en) * | 1998-11-23 | 2007-06-21 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
| CN100406065C (zh) * | 2000-12-01 | 2008-07-30 | 细胞工厂治疗公司 | 糖基化/半乳糖基化肽、双官能接头和核苷酸单体/多聚体的缀合物以及相关的组合物和使用方法 |
| US20030073618A1 (en) * | 2001-02-08 | 2003-04-17 | Kozhemyakin Leonid A. | Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof |
| KR100985457B1 (ko) * | 2001-06-21 | 2010-10-06 | 다이나박스 테크놀로지 코퍼레이션 | 키메라 면역조절 화합물 및 그것들의 사용 방법 |
| US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
| WO2007011722A2 (en) * | 2005-07-15 | 2007-01-25 | President And Fellows Of Harvard College | Reaction discovery system |
| CA2679393A1 (en) * | 2007-03-05 | 2008-09-12 | Newsouth Innovations Pty Limited | Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents |
| CN107365339A (zh) * | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| JP2015529073A (ja) * | 2012-08-20 | 2015-10-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物可逆性基を有するポリヌクレオチド |
-
2014
- 2014-11-06 CN CN201480072173.2A patent/CN106061981A/zh active Pending
- 2014-11-06 EP EP14860025.7A patent/EP3066105A4/en not_active Withdrawn
- 2014-11-06 CA CA2929651A patent/CA2929651A1/en not_active Abandoned
- 2014-11-06 JP JP2016553242A patent/JP2016537027A/ja active Pending
- 2014-11-06 WO PCT/US2014/064401 patent/WO2015069932A1/en not_active Ceased
- 2014-11-06 AU AU2014346658A patent/AU2014346658A1/en not_active Abandoned
- 2014-11-06 US US15/034,973 patent/US20160257961A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610841B1 (en) * | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
| CN102459302A (zh) * | 2009-06-01 | 2012-05-16 | 加利福尼亚大学董事会 | 核酸递送组合物及其使用方法 |
| WO2013126034A1 (en) * | 2012-02-22 | 2013-08-29 | Chemgenes Corporation | Synthesis of high purity dmt-c3-disulfide phosphoramidite |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105037739A (zh) * | 2015-07-28 | 2015-11-11 | 四川大学 | 具有精氨酸穿膜作用的还原敏感型聚合物及其制备方法与应用 |
| CN105037739B (zh) * | 2015-07-28 | 2017-10-27 | 四川大学 | 具有精氨酸穿膜作用的还原敏感型聚合物及其制备方法与应用 |
| US11981703B2 (en) | 2016-08-17 | 2024-05-14 | Sirius Therapeutics, Inc. | Polynucleotide constructs |
| CN110023321A (zh) * | 2016-08-17 | 2019-07-16 | 索尔斯蒂斯生物有限公司 | 多核苷酸构建体 |
| CN109982998A (zh) * | 2016-11-23 | 2019-07-05 | 癌靶技术有限责任公司 | 白蛋白结合psma抑制剂 |
| CN109384715B (zh) * | 2018-11-19 | 2021-09-03 | 复旦大学附属肿瘤医院 | 前列腺特异性膜抗原的小分子抑制剂的制备方法 |
| CN109384715A (zh) * | 2018-11-19 | 2019-02-26 | 复旦大学附属肿瘤医院 | 前列腺特异性膜抗原的小分子抑制剂的制备方法 |
| CN115244064A (zh) * | 2018-12-28 | 2022-10-25 | 圣诺制药公司 | 治疗性分子的靶向递送 |
| CN112402620A (zh) * | 2020-12-07 | 2021-02-26 | 南开大学 | 肿瘤微环境还原响应性的纳米药物及其制备方法 |
| WO2022161452A1 (zh) * | 2021-01-28 | 2022-08-04 | 南京桦冠生物技术有限公司 | 缀合物及其用途 |
| WO2024093947A1 (zh) * | 2022-10-31 | 2024-05-10 | 大睿生物医药科技(上海)有限公司 | 向细胞内递送siRNA的前药 |
| CN115925586A (zh) * | 2022-11-01 | 2023-04-07 | 青岛蓝谷多肽生物医药科技有限公司 | 一种靶向psma的母体及其衍生物的制备方法 |
| CN116715624A (zh) * | 2023-06-14 | 2023-09-08 | 信阳师范学院 | 一种n-烷基化吡啶硫酮类化合物的合成方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2929651A1 (en) | 2015-05-14 |
| AU2014346658A1 (en) | 2016-06-02 |
| EP3066105A4 (en) | 2017-10-11 |
| US20160257961A1 (en) | 2016-09-08 |
| WO2015069932A1 (en) | 2015-05-14 |
| JP2016537027A (ja) | 2016-12-01 |
| EP3066105A1 (en) | 2016-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200392498A1 (en) | Polynucleotide constructs having bioreversible and non-bioreversible groups | |
| US20160257961A1 (en) | Polynucleotide constructs having disulfide groups | |
| US20240247025A1 (en) | Polynucleotide constructs | |
| US9950001B2 (en) | Polynucleotides having bioreversible groups | |
| KR20150056647A (ko) | 구아니딘 가교를 갖는 인공 뉴클레오시드 및 올리고뉴클레오티드 | |
| US20190194655A1 (en) | Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate | |
| WO2023045995A1 (en) | Multivalent Ligand Clusters with Diamine Scaffold for Targeted Delivery of Therapeutic Agents | |
| KR20250174651A (ko) | 5'-포스포네이트 변형 뉴클레오시드 유사체 및 이로부터 제조된 올리고뉴클레오티드 | |
| CN119730859A (zh) | 用于抑制超氧化物歧化酶1(SOD1)表达的RNAi剂、其组合物及使用方法 | |
| CA3125289A1 (en) | Targeted delivery of therapeutic molecules | |
| JP2025536115A (ja) | 膜貫通送達系およびその使用 | |
| US20030162739A1 (en) | Antisense molecules and method of controlling expression of gene function by using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161026 |